Armetheon Announces Positive Results of Pharmacokinetics Study of Tecarfarin versus Warfarin

MILPITAS, Calif., Aug. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced results from its Phase 1 clinical trial eva... Biopharmaceuticals, Cardiology Armetheon, tecarfarin, warfarin, anticoagulant

Source: HSMN NewsFeed - August 25, 2016 Category: Pharmaceuticals Source Type: news